Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

Daniel R Feikin, Melissa M Higdon, Laith J Abu-Raddad and 11 more

The Lancet · 2022 · Meta-analysis · CC BY

Abstract

Background. Knowing whether COVID-19 vaccine effectiveness wanes is crucial for informing vaccine policy, such as the need for and timing of booster doses. We aimed to systematically review the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination.

Methods. This study was designed as a systematic review and meta-regression. We did a systematic review of preprint and peer-reviewed published article databases from June 17, 2021, to Dec 2, 2021. Randomised controlled trials of COVID-19 vaccine efficacy and observational studies of COVID-19 vaccine effectiveness were eligible. Studies with vaccine efficacy or effectiveness estimates at discrete time intervals of people who had received full vaccination and that met predefined screening criteria underwent full-text review. We used random-effects meta-regression to estimate the average change in vaccine efficacy or effectiveness 1–6 months after full vaccination.

Findings. Of 13 744 studies screened, 310 underwent full-text review, and 18 studies were included (all studies were carried out before the omicron variant began to circulate widely). Risk of bias, established using the risk of bias 2 tool for randomised controlled trials or the risk of bias in non-randomised studies of interventions tool was low for three studies, moderate for eight studies, and serious for seven studies. We included 78 vaccine-specific vaccine efficacy or effectiveness evaluations (Pfizer–BioNTech-Comirnaty, n=38; Moderna-mRNA-1273, n=23; Janssen-Ad26.COV2.S, n=9; and AstraZeneca-Vaxzevria, n=8). On average, vaccine efficacy or effectiveness against SARS-CoV-2 infection decreased from 1 month to 6 months after full vaccination by 21·0 percentage points (95% CI 13·9–29·8) among people of all ages and 20·7 percentage points (10·2–36·6) among older people (as defined by each study, who were at least 50 years old). For symptomatic COVID-19 disease, vaccine efficacy or effectiveness decreased by 24·9 percentage points (95% CI 13·4–41·6) in people of all ages and 32·0 percentage points (11·0–69·0) in older people. For severe COVID-19 disease, vaccine efficacy or effectiveness decreased by 10·0 percentage points (95% CI 6·1–15·4) in people of all ages and 9·5 percentage points (5·7–14·6) in older people. Most (81%) vaccine efficacy or effectiveness estimates against severe disease remained greater than 70% over time.

Interpretation. COVID-19 vaccine efficacy or effectiveness against severe disease remained high, although it did decrease somewhat by 6 months after full vaccination. By contrast, vaccine efficacy or effectiveness against infection and symptomatic disease decreased approximately 20–30 percentage points by 6 months. The decrease in vaccine efficacy or effectiveness is likely caused by, at least in part, waning immunity, although an effect of bias cannot be ruled out. Evaluating vaccine efficacy or effectiveness beyond 6 months will be crucial for updating COVID-19 vaccine policy.

Funding. Coalition for Epidemic Preparedness Innovations.

References 49

1.
WHO. Guidance document: status of COVID-19 vaccines within WHO EUL/PQ evaluation process. 2021.
Not in our library
2.
WHO. COVID-19 weekly epidemiological update, edition 50, 27 July 2021. 2021.
Not in our library
3.
Harder T, Koch J, Vygen-Bonnet S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26.
Not in our library10.2807/1560-7917.es.2021.26.28.2100563
4.
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021 · 2021
No notice
5.
Higdon MM, Wahl B, Jones CB, et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. medRxiv. 2021.
Not in our library10.1101/2021.09.17.21263549
6.
Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021;29:1075-1090.
Not in our library10.1007/s10787-021-00839-2
7.
Meggiolaro A, Schepisi MS, Nikolaidis G, Mipatrini D, Siddu A, Rezza G. Effectiveness of vaccination against symptomatic and asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. medRxiv. 2021.
Not in our library10.1101/2021.08.25.21262529
8.
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
No notice
9.
International Vaccine Access Center. Results of COVID-19 vaccine effectiveness & impact studies: an ongoing systematic review, methods. 2021.
Not in our library
10.
Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. New Engl J Med. 2021;385:e85.
Not in our library10.1056/nejmoa2114228
11.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.
Not in our library10.1136/bmj.i4919
12.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.
Not in our library10.1136/bmj.l4898
13.
Weekly epidemiological update on COVID-19. Nov 2, 2021.
Not in our library
14.
Breslow NE, Day NE. The design and analysis of cohort studies. 1987;vol 2:1-406.
Not in our library
15.
Kleinbaum DG, Kupper LL, Morgenstern H. 1982.
Not in our library
16.
Kertes J, Gez SB, Saciuk Y, et al. Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO. medRxiv. 2021.
Not in our library10.1101/2021.09.01.21262957
17.
Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ. 2021;375.
Not in our library10.1136/bmj-2021-067873
18.
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine · 2021
No notice
19.
El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. New Engl J Med. 2021;385:1774-1785.
Not in our library10.1056/nejmoa2113017
20.
Thomas SJ, Moreira ED, Kitchin N, et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. 2021.
Not in our library10.1101/2021.07.28.21261159
21.
US Food and Drug Administration. FDA briefing document, EUA amendment request for a booster dose for the Janssen COVID-19 vaccine. Oct 15, 2021.
Not in our library
22.
Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. New Engl J Med. 2021;385:e83.
Not in our library10.1056/nejmoa2114114
23.
Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26.
Not in our library10.2807/1560-7917.es.2021.26.39.2100894
24.
Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. New Engl J Med. 2021;385:1355-1371.
Not in our library10.1056/nejmoa2110362
25.
Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv. 2021.
Not in our library10.1101/2021.09.15.21263583
26.
Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. medRxiv. 2021.
Not in our library10.1101/2021.09.29.21264199
27.
Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions: United States, March–August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1337-1343.
Not in our library10.15585/mmwr.mm7038e1
28.
Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407-1416.
Not in our library10.1016/s0140-6736(21)02183-8
29.
Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of covid-19 vaccines in the United States over 9 months: surveillance data from the state of North Carolina. medRxiv. 2021.
Not in our library10.1101/2021.10.25.21265304
30.
Nordström P, Ballin M, Nordström A. Effectiveness of covid-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. SSRN. 2021.
Not in our library10.2139/ssrn.3949410
31.
Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. 2021.
Not in our library10.1101/2021.10.26.21265397
32.
Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults: United States, March–July 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1156-1162.
Not in our library10.15585/mmwr.mm7034e2
33.
Irizarry RA, Robles-Fontán MM, Nieves EG, Cardona-Gerena I. Time-varying effectiveness of three COVID-19 vaccines in Puerto Rico. SSRN. 2021.
Not in our library10.2139/ssrn.3957118
34.
Poukka E, Baum U, Palmu AA, et al. Cohort study of covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020–October 2021. medRxiv. 2021.
Not in our library10.1101/2021.11.03.21265791
35.
Hall V, Foulkes S, Insalata F, et al. Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021. medRxiv. 2021.
Not in our library10.1101/2021.11.29.21267006
36.
Baden LR, Sahly HME, Essink B, et al. Covid-19 in the phase 3 trial of mRNA-1273 during the Delta-variant surge. medRxiv. 2021.
Not in our library10.1101/2021.09.17.21263624
37.
US Food and Drug Administration. BNT162b2 [Comirnaty (COVID-19 vaccine, mRNA)] evaluation of a booster dose (third dose) vaccines and related biological products advisory committee briefing document. 2021.
Not in our library
38.
Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 vaccine effectiveness in New York state. N Engl J Med. 2022;386:116-127.
Not in our library10.1056/nejmoa2116063
39.
Dolgin E. COVID vaccine immunity is waning: how much does that matter? Nature. 2021;597:606-607.
Not in our library10.1038/d41586-021-02532-4
40.
Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2021.
Not in our library10.1007/s15010-021-01664-z

All 49 references

Cited by papers we hold 8

Targeted protein degradation: advances in drug discovery and clinical practice · 2024
No notice
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression · 2023
No notice
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity · 2023
No notice
The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model · 2022
Not checked
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022
Corrected
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study · 2022
No notice
A multinational Delphi consensus to end the COVID-19 public health threat · 2022
No notice
Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.